Human Septal Cartilage Tissue Engineering: Current Methodologies and Future Directions
Pham TB., Sah RL., Masuda K., Watson D.
Narrative Review, published in Bioengineering (Basel) (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Bioengineering (Basel) (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39593783
- PMCID
- PMC11592323
- DOI
- 10.3390/bioengineering11111123
- Citations
- 2
Abstract (original English)
Nasal septal cartilage tissue engineering is a promising and dynamic field with the potential to provide surgical options for patients with complex reconstruction needs and mitigate the risks incurred by other tissue sources. Developments in cell source selection, cell expansion, scaffold creation, and three-dimensional (3D) bioprinting have advanced the field in recent years. The usage of medicinal signaling cells and nasal chondroprogenitor cells can enhance chondrocyte proliferation, stimulate chondrocyte growth, and limit chondrocyte dedifferentiate. New scaffolds combined with recent innovations in 3D bioprinting have allowed for the creation of more durable and customizable constructs. Future developments may increase technical accessibility and manufacturability, and lower costs, to help incorporate these methods into pre-clinical studies and clinical applications of septal cartilage tissue engineering.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.